Acute Agitation and Aggression Treatment Market Report 2025

This Acute Agitation and Aggression Treatment market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The alzheimer’s disease treatment market size has grown strongly in recent years. It will grow from $5.93 billion in 2024 to $6.41 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to advancements in research and understanding, drug approvals and market entry, government initiatives and funding, public awareness and education.

The alzheimer’s disease treatment market size is expected to see strong growth in the next few years. It will grow to $8.35 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to precision medicine approaches, rising healthcare expenditure, global burden of disease, genetic and biomarker research, emerging markets. Major trends in the forecast period include biotechnological breakthroughs, technological innovations, digital health technologies, precision medicine approaches, neuroinflammation modulation, collaborations and partnerships.

The rising incidence of Alzheimer's disease stands as a significant driver fueling the expansion of the Alzheimer’s disease treatment market. Alzheimer's, the most prevalent form of dementia, is anticipated to witness a notable increase in cases, particularly in the geriatric population. Projections from the USA Alzheimer's Association indicate a projected rise of at least 14% in Alzheimer’s patients across all US states by 2025, primarily attributed to the aging population. Globally, new cases of Alzheimer’s are expected to surge by 35% to 615,000 by 2030 and further increase by 110% to 959,000 by 2050. Consequently, the escalating prevalence of Alzheimer’s disease is anticipated to stimulate the demand, fostering the growth of the global Alzheimer’s disease treatment market.

Government initiatives are poised to be a key driver propelling the Alzheimer's disease treatment market forward. Government initiatives, encompassing plans and actions undertaken by governments to address specific health issues, play a crucial role in Alzheimer's disease treatment. These initiatives involve funding research projects and clinical trials for new drugs and treatments. An example is the National Institutes of Health (NIH), a prominent US-based biomedical and public health research agency, which witnessed an increase in spending on Alzheimer's and dementia research funding. In March 2022, funding escalated by $289 million, reaching a total of $3.5 billion. Consequently, government initiatives contribute significantly to steering the growth of the Alzheimer's disease treatment market.

Major companies in the Alzheimer's disease treatment market are concentrating on obtaining regulatory approvals to gain a competitive advantage and enhance their product offerings. Regulatory approvals refer to the official authorization granted by government agencies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), allowing a product to be marketed and sold to the public. For example, in July 2024, Eli Lilly and Company, a US-based pharmaceutical firm, received FDA approval for its Alzheimer's treatment, Kisunla (donanemab-azbt), which is intended for adults with early symptomatic Alzheimer's disease, including those experiencing mild cognitive impairment and mild dementia. The drug is administered through monthly intravenous infusions and has shown effectiveness in slowing the disease's progression during clinical trials. The approval highlights its potential significance, having received Fast Track, Priority Review, and Breakthrough Therapy designations.

Major companies in the Alzheimer's disease treatment market are concentrating on developing innovative products such as assay kits to offer reliable services. Assay kits, comprised of reagents and materials for specific analytical tests, measure specific analytes. For example, Sysmex Corporation, a Japan-based healthcare company, launched the HISCL β-Amyloid 1-42 Assay Kit and the HISCL β-Amyloid 1-40 Assay Kit in June 2023. These products measure Aβ levels in blood, aiding in identifying Aβ accumulation in the brain, a hallmark of Alzheimer's disease. Sysmex's Automated Immunoassay System HISCL-5000/HISCL-800 facilitates the identification of brain Aβ accumulation, benefiting patients with suspected Aβ accumulation by alleviating financial, emotional, and physical burdens.

In February 2023, Lantheus Holdings Inc., a US-based provider of diagnostic imaging agents, acquired Cerveau Technologies, Inc., a move that is expected to expand Lantheus' imaging portfolio into Alzheimer’s disease. Cerveau Technologies, Inc., based in the US, is known for providing information and technology to researchers and clinicians, aligning with Lantheus' vision to broaden its footprint in Alzheimer's disease imaging.

Alzheimer's disease treatment refers to medications specifically designed to address and manage Alzheimer's, a neurodegenerative disorder. This treatment, categorized as immunotherapy, focuses on targeting the protein beta-amyloid to reduce amyloid plaques, which are associated with Alzheimer's disease. The progression of this disease results in severe memory impairment, often leading to the loss of the ability to perform everyday tasks.

The main types of drugs in Alzheimer's disease treatment include cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors, also known as acetylcholinesterase inhibitors, belong to a class of drugs that work to prevent the normal breakdown of acetylcholine. Different drug classes within Alzheimer's disease treatment encompass cholinergic, memantine, combined drugs, AChE inhibitors, and immunoglobulins, involving various therapeutic approaches such as cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutic methods.

The alzheimer’s disease treatment market research report is one of a series of new reports that provides alzheimer’s disease treatment market statistics, including alzheimer’s disease treatment industry global market size, regional shares, competitors with an alzheimer’s disease treatment market share, detailed Alzheimer’s disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the alzheimer’s disease treatment industry. This alzheimer’s disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Major companies operating in the alzheimer’s disease treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Merck Sharp & Dohme Corp., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., UCB S.A., Eisai Co. Ltd., Forest Laboratories LLC, Ono Pharmaceutical Co. Ltd., H. Lundbeck A/S, Allergan plc, Luye Pharma Group, Avanir Pharmaceuticals Inc., Denali Therapeutics Inc., Athira Pharma Inc., ProMIS Neurosciences Inc., AC Immune SA, vTv Therapeutics Inc., AB Science SA, TauRx Pharmaceuticals Ltd., Alzheon Inc.

North America is the largest region in the alzheimer's disease treatment market in 2024. Middle East is expected to be the fastest growing region in the alzheimer’s disease treatment market share during the forecast period. The regions covered in the alzheimer’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alzheimer’s disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The alzheimer’s disease treatment market includes revenues earned by entities by temporarily improve symptoms of memory loss and problems with thinking and reasoning. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.